RxDoctor Payments Data

Apolinar Bordador, MD

Internal Medicine · Little Rock, ARNPI 1679862023

Payments from drug & device makers

$360in general payments, 2019–2025

Across 14 payments — averaging $25.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$125
  • AbbVie$74
  • GSK$32
  • Novo Nordisk$31
  • Polynovo North America LLC$24
  • Boston Scientific$19
  • plus $54 from 4 others

What the payments were for

  • Food & beverage$360100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$360 in reported general payments places this provider in the 55th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$195,401
Medicare patients
338
Services billed
8,019

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide113$113,886
MounjaroTirzepatide43$42,501
EliquisApixaban63$41,779
TrulicityDulaglutide16$22,643
NeurontinGabapentin12$17,255
LinzessLinaclotide14$12,730
FarxigaDapagliflozin Propanediol17$12,478
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$11,943
JardianceEmpagliflozin12$11,367
JanuviaSitagliptin Phosphate15$10,129
Potassium Chloride125$6,222
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$4,887
Duloxetine Hcl177$4,610
VascepaIcosapent Ethyl12$4,609
Levothyroxine Sodium365$4,020

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$31$113,886113 claims
Lilly USA, LLCMounjaro, Trulicity$15$65,14459 claims
AbbVieLinzess, Synthroid$74$15,19952 claims
GSKTrelegy Ellipta$32$11,94313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →